Psychedelic Science Org UK

"Psychedelics could be for psychiatry what the microscope is for biology or the telescope for astronomy."

What is Psychedelic Science Org UK?

Psychedelic Science Org UK is a crowd-funding campaign that aims to raise funds for scientific research with psychedelic drugs, with a special focus on a clinical trial assessing the safety and efficacy of psilocybin as a treatment for depression.

Depression

Depression is a serious global problem. It’s the leading cause of disability worldwide, is linked to over half of all suicides, and affects some 350 million people. Worse still, the prevalence of depression is increasing; the World Health Organisation estimates that depression will become the leading overall contributor to the global burden of disease by 2030.

Psilocybin

Psilocybin changes brain activity in a manner that is consistent with a large range of effective treatments for depression. More specifically, we found that circuits that are over-active and reinforced in depression become loosened and normalised under psilocybin. Psilocybin works to mimic some serotonin actions. That psilocybin does this, may explain why it may be useful in depression.

Help Us

All research depends on funding and if the funds aren’t there, the research simply can’t happen.So, if you believe in our vision and conviction to try and improve the lives of patients suffering from depression, then please give us your support! This is an incredibly worthwhile cause and we are perfectly placed to deliver on it.

Our Story

In 2012, Imperial College London were awarded a research grant from the UK government’s Medical Research Council (MRC) to set-up a clinical trial to investigate the antidepressant potential of psilocybin. The study is sponsored by Imperial College London and has ethical approval. The UK Home Office have licensed the importation and storage of the psilocybin that we will use.

Our Team

Key members
Dr Robin Carhart Harris (Founder)
Post-doctoral Researcher, Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London
Professor David Nutt
David Nutt (Founder) is currently the Edmond J Safra Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences.
Dr James Rucker
Psychiatrist South London, Lecturer Kings College London,founder of the Maudsley Psychedelic Society

Testimonials

Messages of support

Research Background Videos

Latest Posts

  • Dec, 11

    Ecstasy users report different sleep to matched controls

    Current and former ecstasy users report different sleep to matched controls: a web-based questionnaire study This study sought to test the association between ecstasy use and abnormal sleep. An anonymous web-based questionnaire containing questions on drug use and sleep was completed by 1035 individuals. From this large sample, a group of 89 ecstasy users were […]

    Read more
    Dec, 11

    Waves of the Unconscious: The Neurophysiology of Dreamlike Phenomena

    Waves of the Unconscious: The Neurophysiology of Dreamlike Phenomena and Its Implications for the Psychodynamic Model of the Mind This paper reviews scientific literature on four subjective states: the dream state, the dreamy state of temporal lobe epilepsy and temporal lobe stimulation, the acute psychotic state, and the psychedelic state. Evidence is cited showing that […]

    Read more
  • Dec, 11

    Was it a vision or a waking dream?

    Was it a vision or a waking dream? A commentary on Disrupting posterior cingulate connectivity disconnects consciousness from the external environment by Herbet, G., Lafargue, G., de Champfleur, N. M., Moritz-Gasser, S., le Bars, E., Bonnetblanc, F., et al. (2014). Neuropsychologia 56C, 239–244. doi: 10.1016/j.neuropsychologia.2014.01.020 Reminiscent of Wilder Penfield’s famous experiments, Neurologists in France have […]

    Read more
    Dec, 11

    How do hallucinogens work on the brain?

    How do hallucinogens work on the brain? Robin Carhart-Harris, Mendel Kaelen and David Nutt consider a big question on several levels The ‘classic’ hallucinogens – such as LSD (derived from ergotamine found in ergot fungi), dimethyltryptamine (DMT, the major hallucinogenic component of ayahuasca) and psilocybin (from magic mushrooms) – possess a unique and arguably unrivalled […]

    Read more
  • Dec, 11

    Spatial Dependencies between Large-Scale Brain Networks

    Spatial Dependencies between Large-Scale Brain Networks Functional neuroimaging reveals both increases (task-positive) and decreases (task-negative) in neural activation with many tasks. Many studies show a temporal relationship between task positive and task negative networks that is important for efficient cognitive functioning. Here we provide evidence for a spatial relationship between task positive and negative networks. […]

    Read more
    Dec, 11

    Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis

    Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis Psilocybin is a classic psychedelic and a candidate drug model of psychosis. This study measured the effects of psilocybin on resting-state network and thalamocortical functional connectivity (FC) using functional magnetic resonance imaging (fMRI). Fifteen healthy volunteers received intravenous infusions of psilocybin and placebo in […]

    Read more
  • Oct, 23

    The effects of psilocybin and MDMA on between-network resting state functional connectivity

    The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers Perturbing a system and observing the consequences is a classic scientific strategy for understanding a phenomenon. Psychedelic drugs perturb consciousness in a marked and novel way and thus are powerful tools for studying its mechanisms. In the present analysis, we […]

    Read more
    Oct, 23

    Cause for a re- think on drug models of psychosis and other psychiatric disorders

    Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders RL Carhart-Harris, S Brugger, DJ Nutt and JM Stone Despite the widespread application of drug modelling in psychiatric research, the relative value of different models has never been formally compared in the same analysis. Here we compared the […]

    Read more
  • Oct, 15

    How Psilocybin Improves Your Brain

    Psilocybin frees the brain from its rigid patterns and ego-driven assumptions, and allows the user to look at the world — and him or herself — from a whole new perspective. Many mushroom experiences also are accompanied by waves of good feelings and psychedelic visions of sound and color.   These results build on other […]

    Read more
    Oct, 15

    The Magic Effect Of Psilocybin Mushrooms

    “These are remarkable compounds, with I think remarkable implications, if we can understand how they work and why they work,” says Roland Griffiths, a scientist at Johns Hopkins University, where some of the world’s leading psychedelic research is taking place.   Psilocybin mushrooms provoke mystical experiences and spiritual journeys when the body breaks the chemical […]

    Read more